Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

15.76 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Jun 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Catalyst Pharm Inc

< Previous 1 2 3 4 5 6 Next >
Small Caps Are On A Tear Including Speculative Biotechs
So far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation. 
Via Talk Markets
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. 
Via Benzinga
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside. 
Via InvestorPlace
Recap: Catalyst Pharmaceuticals Q3 Earnings
Via Benzinga
Why the growth investor may take a look at NASDAQ:CPRX.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
5 Analysts Have This to Say About Catalyst Pharmaceuticals
Via Benzinga
3 Robinhood Stocks to Buy Right Now
The no-cost trading platform's customers have their clear favorites, and they're more mainstream names than you might expect them to be. 
Via The Motley Fool
2 Robinhood Stocks With Market-Beating Potential
These diamonds in the rough won't stay down. 
Via The Motley Fool
10 Best Defensive Stocks To Invest In 2023
A defensive stock is a stock that demonstrates relatively stable performance regardless of the current state of the economy. Defensive stocks are less prone to the economic cycle of expansions and... 
Via Talk Markets
Topics Economy
Exposures Economy
Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+
Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81. 
Via Investor's Business Daily
ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold
One key metric to look for in a stock is an 80-plus Relative Strength Rating. ACELYRIN stock hit that mark on Tuesday, with a jump to 81. 
Via Investor's Business Daily
Where Catalyst Pharmaceuticals Stands With Analysts
Via Benzinga
The Latest Analyst Ratings for Catalyst Pharmaceuticals
Via Benzinga
Catalyst Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
1 Growth Stock to Buy Before the Next Bull Market
The stock is on a roll, and the company just made a major new purchase. 
Via The Motley Fool
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
Exelixis Stock Sees Rising Relative Strength Rating
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before. 
Via Investor's Business Daily
7 ‘Strong Buy’ Value Stocks You Should Be Loading Up On Now
Although ultra-cheap ideas tend to carry significant risks, these strong buy value stocks offer the endorsement of analysts. 
Via InvestorPlace
7 Little-Known Stocks to Buy Now Before They Become the Next Big Thing
Although people might not readily recognize these little-known stocks, they offer surprisingly robust upside potential. 
Via InvestorPlace
ETF Returns: Mid-Cap Winners And Losers
We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on... 
Via Benzinga
Analyst Expectations for Catalyst Pharmaceuticals's Future
Via Benzinga
Truist Securities Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know
Via Benzinga
The 7 Best Stocks Under $15 to Buy in June 2023
While you generally get what you pay for, these best stocks under $15 for June provide compelling opportunities at discount. 
Via InvestorPlace
Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy?
When evaluating investments, it helps to keep quarterly performance in context. 
Via The Motley Fool
Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81. 
Via Investor's Business Daily
Market Rally Diverges; Google Surges On AI News, Inflation Cools, But Breadth Weak: Weekly Review
The Nasdaq hit a new 2023 high, but not the S&P 500 or Dow Jones. 
Via Investor's Business Daily
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales. 
Via Benzinga
IBD 50 Leader And No. 1 Biotech Catalyst Puts Up 128% Earnings Growth
Though Catalyst's unadjusted earnings missed forecasts, they grew by triple digits. 
Via Investor's Business Daily
7 A-Rated Stocks to Buy for April 2023
Now that the first quarter's in the bank, here are seven A-rated stocks to buy for April to keep your portfolio in top-notch shape. 
Via InvestorPlace
2 Top Growth Stocks That Can Withstand an Economic Downturn
These two drugmakers should march higher in 2023 and beyond. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.